Ajanta Pharma AJANTPHARM
Branded generics in India (cardiac, ophthalmology, derma), Asia and Africa, plus a US generics business
Mapped in 1 theme: Pharmaceuticals.
Where Ajanta Pharma sits in the supply chain
Ajanta Pharma appears in 2 supply-chain layers in one theme, Pharmaceuticals.
Pharmaceuticals › India branded formulations
OperatorOther companies in this layer
Pharmaceuticals › Generics (US & export)
Direct supplierOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 4,209 | 4,648 | 5,453 |
| Net profit | 816 | 920 | 1,056 |
Latest-year revenue ₹5,453 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- ~70% of revenue from branded markets (India, Asia, Africa) - less exposed to US price erosion
- High returns on capital and consistent dividend/buyback payouts
- India growth above market in chronic niches
Risks
- Africa institutional anti-malarial business is tender-driven
- US is a smaller, price-eroding generics book
- Currency risk in African and Asian markets
Common questions
What does Ajanta Pharma do?
Branded generics in India (cardiac, ophthalmology, derma), Asia and Africa, plus a US generics business.
Where does Ajanta Pharma sit in the supply chain?
Ajanta Pharma (NSE: AJANTPHARM) is mapped in 2 supply-chain layers: India branded formulations (Pharmaceuticals) and Generics (US & export) (Pharmaceuticals).
Who are Ajanta Pharma's peers?
In the India branded formulations layer of Pharmaceuticals: Sun Pharmaceutical Industries, Mankind Pharma, Torrent Pharmaceuticals, Alkem Laboratories, Abbott India, Eris Lifesciences and 4 more.
What is Ajanta Pharma's market cap and valuation?
As of 30 Oct 2026: market cap ₹43,844 Cr, P/E 34.7x, ROCE 34.5%, ROE 27.1%, dividend yield 0.91%.